Difference between revisions of "How I Treat"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
(2 intermediate revisions by the same user not shown)
Line 39: Line 39:
 
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
 
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
 
*'''2016:''' Pratz & Levis. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5290983/ How I treat FLT3-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/27872057/ PubMed]
 
*'''2016:''' Pratz & Levis. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5290983/ How I treat FLT3-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/27872057/ PubMed]
*'''2015:''' Röllig & Ehninger. [http://www.bloodjournal.org/content/125/21/3246.long How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed]
+
*'''2015:''' Röllig & Ehninger. [https://doi.org/10.1182/blood-2014-10-551507 How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed]
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
+
*'''2014:''' Ossenkoppele & Löwenberg. [https://doi.org/10.1182/blood-2014-08-551499 How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 +
**'''2000:''' Estey. [https://doi.org/10.1182/blood.V96.5.1670 How I treat older patients with AML] [https://pubmed.ncbi.nlm.nih.gov/10961861/ PubMed]
 
*'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed]
 
*'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed]
  
Line 49: Line 50:
 
===[[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]===
 
===[[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]===
 
*'''2022:''' Berman. [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia]
 
*'''2022:''' Berman. [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia]
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
+
*'''2019:''' Hijiya & Suttorp. [https://doi.org/10.1182/blood.2018882233 How I treat chronic myeloid leukemia in children and adolescents] [https://pubmed.ncbi.nlm.nih.gov/30917954/ PubMed]
 
*'''2016:''' Gotlib. [https://doi.org/10.1182/blood-2016-08-693630 How I treat atypical chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/27899359/ PubMed]
 
*'''2016:''' Gotlib. [https://doi.org/10.1182/blood-2016-08-693630 How I treat atypical chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/27899359/ PubMed]
 
*'''2012:''' Cortes & Kantarjian. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4916560/ How I treat newly diagnosed chronic phase CML] [https://pubmed.ncbi.nlm.nih.gov/22613793/ PubMed]
 
*'''2012:''' Cortes & Kantarjian. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4916560/ How I treat newly diagnosed chronic phase CML] [https://pubmed.ncbi.nlm.nih.gov/22613793/ PubMed]
Line 65: Line 66:
 
*'''2018:''' Steensma. [https://doi.org/10.1182/blood-2018-06-860882 How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/30185432/ PubMed]
 
*'''2018:''' Steensma. [https://doi.org/10.1182/blood-2018-06-860882 How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/30185432/ PubMed]
 
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
 
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
*'''2013:''' Sekeres & Cutler. [http://www.bloodjournal.org/content/123/6/829.long How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed]
+
*'''2013:''' Sekeres & Cutler. [https://doi.org/10.1182/blood-2013-08-496935 How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed]
 
*'''2013:''' Fenaux & Adès. [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
 
*'''2013:''' Fenaux & Adès. [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
  
Line 100: Line 101:
 
===[[Castleman disease]]===
 
===[[Castleman disease]]===
 
*'''2022:''' Brandstadter & Fajgenbaum. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9584165/ How we manage idiopathic multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/36125948/ PubMed]
 
*'''2022:''' Brandstadter & Fajgenbaum. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9584165/ How we manage idiopathic multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/36125948/ PubMed]
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
+
*'''2010:''' Bower. [https://doi.org/10.1182/blood-2010-07-290213 How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
  
 
===[[Chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL/SLL)]]===
 
===[[Chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL/SLL)]]===
Line 136: Line 137:
 
*'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed]
 
*'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed]
 
*'''2012:''' Dunleavy & Wilson. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3321851/ How I treat HIV-associated lymphoma] [https://pubmed.ncbi.nlm.nih.gov/22337719/ PubMed]
 
*'''2012:''' Dunleavy & Wilson. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3321851/ How I treat HIV-associated lymphoma] [https://pubmed.ncbi.nlm.nih.gov/22337719/ PubMed]
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long  How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
+
*'''2010:''' Bower. [https://doi.org/10.1182/blood-2010-07-290213 How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
  
 
===[[Large granular lymphocytic leukemia|Large granular lymphocytic leukemia (T-LGL)]]===
 
===[[Large granular lymphocytic leukemia|Large granular lymphocytic leukemia (T-LGL)]]===
Line 145: Line 146:
  
 
===[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]===
 
===[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]===
*'''2013:''' Tse & Kwong. [http://www.bloodjournal.org/content/121/25/4997.long How I treat NK/T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23652805/ PubMed]
+
*'''2013:''' Tse & Kwong. [https://doi.org/10.1182/blood-2013-01-453233 How I treat NK/T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23652805/ PubMed]
  
 
===[[Hodgkin lymphoma, nodular lymphocyte-predominant|Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)]]===
 
===[[Hodgkin lymphoma, nodular lymphocyte-predominant|Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)]]===
Line 366: Line 367:
 
*'''2020:''' Hunger & Raetz. [https://doi.org/10.1182/blood.2019004043 How I treat relapsed acute lymphoblastic leukemia in the pediatric population] [https://pubmed.ncbi.nlm.nih.gov/32589723/ PubMed]
 
*'''2020:''' Hunger & Raetz. [https://doi.org/10.1182/blood.2019004043 How I treat relapsed acute lymphoblastic leukemia in the pediatric population] [https://pubmed.ncbi.nlm.nih.gov/32589723/ PubMed]
 
*'''2020:''' Teachey & O'Connor [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6966932/ How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children] [https://pubmed.ncbi.nlm.nih.gov/31738819/ PubMed]
 
*'''2020:''' Teachey & O'Connor [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6966932/ How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children] [https://pubmed.ncbi.nlm.nih.gov/31738819/ PubMed]
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
+
*'''2019:''' Hijiya & Suttorp. [https://doi.org/10.1182/blood.2018882233 How I treat chronic myeloid leukemia in children and adolescents] [https://pubmed.ncbi.nlm.nih.gov/30917954/ PubMed]
 
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
 
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
Line 373: Line 374:
 
===Adolescents and young adults (AYA)===
 
===Adolescents and young adults (AYA)===
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
+
*'''2019:''' Hijiya & Suttorp. [https://doi.org/10.1182/blood.2018882233 How I treat chronic myeloid leukemia in children and adolescents] [https://pubmed.ncbi.nlm.nih.gov/30917954/ PubMed]
 
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
Line 387: Line 388:
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 
*'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease]
 
*'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease]
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
+
*'''2014:''' Ossenkoppele & Löwenberg. [https://doi.org/10.1182/blood-2014-08-551499 How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 +
**'''2000:''' Estey. [https://doi.org/10.1182/blood.V96.5.1670 How I treat older patients with AML] [https://pubmed.ncbi.nlm.nih.gov/10961861/ PubMed]
 
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
 
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
  

Revision as of 23:22, 27 June 2024

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in Blood, there are a few exceptions.

In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Malignant hematology

Acute leukemias

Mixed-phenotype acute leukemia (MPAL)

Myeloid neoplasms

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Acute promyelocytic leukemia (APL)

Chronic myeloid leukemia (CML)

Chronic myelomonocytic leukemia (CMML)

Hypereosinophilic syndrome (HES)

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasms (MPNs)

Essential thrombocythemia (ET)

Myelofibrosis (MF)

Polycythemia vera (PV)

Systemic mastocytosis

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

Anaplastic large cell lymphoma

Burkitt lymphoma (BL)

Castleman disease

Chronic lymphocytic leukemia (CLL/SLL)

Classical Hodgkin lymphoma (cHL)

CNS lymphoma

Cutaneous T-cell lymphoma (CTCL)

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

High-grade B-cell lymphoma (HGBL)

HIV-associated lymphoma

Large granular lymphocytic leukemia (T-LGL)

Mantle cell lymphoma (MCL)

NK- and T-cell lymphoma (NKTCL)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)

Peripheral T-cell lymphoma (PTCL)

Post-transplant lymphoproliferative disorder (PTLD)

Primary mediastinal B-cell lymphoma (PMBCL)

Prolymphocytic leukemia (T-PLL)

Splenic lymphoma

Transformed lymphoma

Waldenström macroglobulinemia (WM)

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

MGUS

Multiple myeloma (MM)

Plasma cell leukemia (PCL)

Smoldering multiple myeloma (SMM)

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

Langerhans cell histiocytosis (LCH)

Classical hematology

Hemostasis and thrombosis

Acquired thrombotic thrombocytopenic purpura (aTTP)

Antiphospholipid antibody syndrome (APS)

Arterial thromboembolism (ATE)

Disseminated intravascular coagulation (DIC)

Hemophilia

Heparin-induced thrombocytopenia (HIT)

Thrombotic microangiopathy (TMA)

Venous thromboembolism (VTE)

von Willebrand disease (vWD)

Cytopenias

Acquired pure red cell aplasia

Anemia

Aplastic anemia

Autoimmune cytopenia

Immune thrombocytopenia (ITP)

Neutropenia & leukopenia

Thrombocytopenia and platelet dysfunction

WHIM syndrome

Hemoglobinopathies

Beta thalassemia

Sickle cell disease

Hemolytic disorders

Cold agglutinin disease (CAD)

Atypical hemolytic uremic syndrome (aHUS)

Paroxysmal nocturnal hemoglobinuria (PNH)

Warm autoimmune hemolytic anemia (WAIHA)

Special considerations

Age-based recommendations

The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.

Neonates

Children

Adolescents and young adults (AYA)

Older adults/Geriatric hematology

Complications of treatment

Bleeding

Cardiovascular complications

Immune effector cells toxicity management

Infectious complications

Iron overload

Medication toxicities

Neurologic medications

Genetic risk

Gynecologic considerations

Menstruation

Pregnancy

Postpartum period

Hospitalization

Regional considerations

Surgical considerations

Transplantation

Allogeneic HSCT

Autologous HSCT

Graft versus host disease (GVHD)

Miscellaneous

Acute respiratory failure

Atrial fibrillation

Cryoglobulinemia

Immunodeficiency

Common variable immune deficiency (CVID)

Severe combined immunodeficiency (SCID)

Priapism

Protoporphyria

T-cell chronic active Epstein-Barr virus disease (CAEBV)